PCVX Vaxcyte, Inc.
USHealthcareAs of 2026-07-10 14:46
Why PCVX matters now
Vaxcyte, Inc. (PCVX) is a US stock in Healthcare. The latest InvestLog snapshot shows $58.45 with -2.31% on the session and $8.44B in market capitalization; recent performance reads 1-month +5.45% and YTD +11.49%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-320.6M, and EPS of $-2.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.4%.
The latest indexable market news headline is "Vaxcyte to Participate in Upcoming Investor Conferences" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $89.00; recent insider activity includes GUGGENHIME ANDREW filing S-Sale; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.40
P/S
0.00
EV/EBITDA
-7.91
DCF Value
$-0.57
FCF Yield
-10.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.5%
ROA
-28.3%
ROIC
-35.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-320.6M | $-2.30 |
| Q4 2025 | $0.00 | $-246.5M | $-1.81 |
| FY 2025 | $0.00 | $-766.6M | $-5.63 |
| Q3 2025 | $0.00 | $-212.8M | $-1.56 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$89.00
Target (Median)
$89.00
Target Range
$89.00 - $89.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.24
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.